Medications for alcohol use disorder improve survival in patients with hazardous drinking and alcohol-associated cirrhosis
Authors:
Top Cited Papers
Open Access
- 24 March 2023
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 7 (4)
Abstract
Background: Medications for alcohol use disorder (MAUD) are highly effective in achieving and maintaining abstinence in patients with alcohol use disorder (AUD). Our aim was to evaluate the effect of MAUD on all-cause mortality in patients with alcohol-associated cirrhosis and active alcohol use. Methods: This was a retrospective cohort study of patients with alcohol-associated cirrhosis and high-risk alcohol use disorder in the Veterans Outcomes and Costs Associated with Liver Disease (VOCAL) database. Propensity score matching for exposure to MAUD (acamprosate or naltrexone) within a year after cirrhosis diagnosis was performed to account for potential confounders, and the association between MAUD and all-cause mortality was subsequently evaluated using Cox regression analysis. Results: A total of 9131 patients were included, of whom 886 (9.7%) were exposed to MAUD (naltrexone: 520, acamprosate: 307, both medications: 59). The duration of MAUD exposure was >3 months in 345 patients (39%). The strongest positive predictor of MAUD prescription was an inpatient diagnosis code for AUD, followed by a concurrent diagnosis of depression; the strongest negative predictor was a history of cirrhosis decompensation. After propensity score matching (866 patients in each group) with excellent covariate balance (absolute standardized mean differences p = 0.024). Conclusion: MAUD are underutilized in patients with alcohol-associated cirrhosis with high-risk alcohol use behavior but are associated with improved survival after adjustment for confounders such as the severity of liver disease, age, and engagement in the healthcare system.Keywords
This publication has 35 references indexed in Scilit:
- Pharmacotherapy for alcohol dependence: Perceived treatment barriers and action strategies among Veterans Health Administration service providers.Psychological Services, 2013
- Comparative performance of the AUDIT-C in screening for DSM-IV and DSM-5 alcohol use disordersDrug and Alcohol Dependence, 2012
- Meta‐analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?Addiction, 2012
- Barriers to Use of Pharmacotherapy for Addiction Disorders and How to Overcome ThemCurrent Psychiatry Reports, 2011
- Naltrexone for the Management of Alcohol DependenceNew England Journal of Medicine, 2008
- Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled studyThe Lancet, 2007
- The validity of viral hepatitis and chronic liver disease diagnoses in Veterans Affairs administrative databasesAlimentary Pharmacology & Therapeutics, 2007
- Combined Pharmacotherapies and Behavioral Interventions for Alcohol DependenceJAMA, 2006
- Rates and predictors of relapse after natural and treated remission from alcohol use disordersAddiction, 2006
- A Model to Predict Survival in Patients With End–Stage Liver DiseaseHepatology, 2001